Literature DB >> 9237759

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity.

R Medzhitov1, P Preston-Hurlburt, C A Janeway.   

Abstract

Induction of the adaptive immune response depends on the expression of co-stimulatory molecules and cytokines by antigen-presenting cells. The mechanisms that control the initial induction of these signals upon infection are poorly understood. It has been proposed that their expression is controlled by the non-clonal, or innate, component of immunity that preceded in evolution the development of an adaptive immune system in vertebrates. We report here the cloning and characterization of a human homologue of the Drosophila toll protein (Toll) which has been shown to induce the innate immune response in adult Drosophila. Like Drosophila Toll, human Toll is a type I transmembrane protein with an extracellular domain consisting of a leucine-rich repeat (LRR) domain, and a cytoplasmic domain homologous to the cytoplasmic domain of the human interleukin (IL)-1 receptor. Both Drosophila Toll and the IL-1 receptor are known to signal through the NF-kappaB pathway. We show that a constitutively active mutant of human Toll transfected into human cell lines can induce the activation of NF-kappaB and the expression of NF-kappaB-controlled genes for the inflammatory cytokines IL-1, IL-6 and IL-8, as well as the expression of the co-stimulatory molecule B7.1, which is required for the activation of naive T cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9237759     DOI: 10.1038/41131

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1398 in total

Review 1.  The role of self-recognition in receptor repertoire development. Members of the Janeway Laboratory.

Authors:  C A Janeway
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity.

Authors:  G Zhang; S Ghosh
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae.

Authors:  J E Wang; A Warris; E A Ellingsen; P F Jørgensen; T H Flo; T Espevik; R Solberg; P E Verweij; A O Aasen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

4.  ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway.

Authors:  E Kopp; R Medzhitov; J Carothers; C Xiao; I Douglas; C A Janeway; S Ghosh
Journal:  Genes Dev       Date:  1999-08-15       Impact factor: 11.361

Review 5.  New insights into the biology of the acute phase response.

Authors:  A F Suffredini; G Fantuzzi; R Badolato; J J Oppenheim; N P O'Grady
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

6.  Toll-like receptors confer responsiveness to lipopolysaccharide from Porphyromonas gingivalis in human gingival fibroblasts.

Authors:  K Tabeta; K Yamazaki; S Akashi; K Miyake; H Kumada; T Umemoto; H Yoshie
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

7.  Suppression of endotoxin- and staphylococcal exotoxin-induced cytokines and chemokines by a phospholipase C inhibitor in human peripheral blood mononuclear cells.

Authors:  T Krakauer
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

8.  Toll receptor-mediated Drosophila immune response requires Dif, an NF-kappaB factor.

Authors:  X Meng; B S Khanuja; Y T Ip
Journal:  Genes Dev       Date:  1999-04-01       Impact factor: 11.361

9.  Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses.

Authors:  Y Shi; W Zheng; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

10.  A family of peptidoglycan recognition proteins in the fruit fly Drosophila melanogaster.

Authors:  T Werner; G Liu; D Kang; S Ekengren; H Steiner; D Hultmark
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.